Kane Biotech Inc.
KNBIF
$0.0643
-$0.002-3.02%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 210.67% | 160.58% | 143.82% | -23.58% | -171.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 210.67% | 160.58% | 143.82% | -23.58% | -171.25% |
| Cost of Revenue | 218.00% | 154.08% | 112.95% | -35.84% | -172.91% |
| Gross Profit | 204.05% | 165.74% | 435.34% | -17.73% | -169.83% |
| SG&A Expenses | 289.35% | 164.92% | 26.15% | -7.23% | -78.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 626.37% | 299.29% | 41.82% | -6.03% | -87.83% |
| Operating Income | -55.37% | -75.92% | -19.03% | 5.07% | 39.54% |
| Income Before Tax | -22.11% | -43.16% | -24.46% | -11.42% | 11.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.11% | -43.16% | -24.46% | -11.42% | 11.82% |
| Earnings from Discontinued Operations | 2,608.42% | 3,751.14% | -224.22% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 231.71% | 222.95% | -31.50% | -27.01% | 7.32% |
| EBIT | -55.37% | -75.92% | -19.03% | 5.07% | 39.54% |
| EBITDA | -61.37% | -83.19% | -22.85% | 3.94% | 39.33% |
| EPS Basic | 226.64% | 214.98% | -26.81% | -20.83% | 15.28% |
| Normalized Basic EPS | -20.57% | -44.03% | -15.79% | 1.20% | 28.79% |
| EPS Diluted | 196.39% | 198.07% | -1.28% | 4.17% | 3.82% |
| Normalized Diluted EPS | -18.12% | -41.98% | -13.82% | 3.01% | 30.30% |
| Average Basic Shares Outstanding | 5.60% | 5.27% | 5.51% | 6.26% | 6.23% |
| Average Diluted Shares Outstanding | 6.25% | 5.94% | 9.87% | 10.72% | 10.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
